



#16
Deal.
2/6/01
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Castillo et al. Examiner: Coe, S.
Serial No.: 09/079,829 Group Art Unit: 1651
Filing Date: 05/15/1998 Attorney Docket No.: PROTEO.P07

Title of Invention: Composition and Methods for Treating Alzheimer's Disease and other Amyloidoses

Seattle, Washington 98109
February 1, 2001

TO THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231


DECLARATION OF DR. ALAN D. SNOW UNDER RULE 131(b)

Alan D. Snow declares:

1. I am over the age of 18, and competent to testify in this matter. I am a co-inventor of the above invention.
2. As of at least as early as January 1, 1997 I first conceived of a pharmacological agent that is a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, with the plant matter and the therapeutic amount of the plant matter particularly selected for efficacy in treating an amyloid disease in a patient.
3. Between 1/1/97 and 5/15/97 when we filed the provisional patent application in this case, I went through the following steps to put my conception into practice:
 - a) At least as early as 1/1/97 my co-inventor Gerardo Castillo and I were testing extraction methods for *Uncaria tomentosa* and testing the invention *in vitro* for efficacy in treating amyloidoses.
 - b) Between approximately 4/15/97 and 5/15/97 when we filed the provisional patent application, patent counsel and I worked on the application and on fullest implementation of best mode particulars for the application. I also continued *in vitro* testing of the invention during that period, making changes and updates to patent application drafts continually during that period.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the accompanying application or any patent issued thereon.

DATED February 1, 2001.


DR. ALAN D. SNOW